Last reviewed · How we verify
MG1111
At a glance
| Generic name | MG1111 |
|---|---|
| Sponsor | GC Biopharma Corp |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination (PHASE2)
- An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years (NA)
- A Study of MG1111 in Healthy Children (PHASE2, PHASE3)
- Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG1111 CI brief — competitive landscape report
- MG1111 updates RSS · CI watch RSS
- GC Biopharma Corp portfolio CI